Annovis Bio Enrolls First Patients in Phase 3 Trial of Buntanetap for Early Alzheimer's Disease

MT Newswires Live2025-02-06

Annovis Bio (ANVS) said Wednesday it enrolled the first two participants in its phase 3 trial of buntanetap for early Alzheimer's disease.

The trial will evaluate the safety and efficacy of a daily dose of buntanetap, with treatment lasting for 18 months.

The study includes a 6-month assessment of symptomatic effects followed by a 12-month evaluation of potential disease-modifying effects. Annovis said it plans to enroll more than 750 patients across about 100 sites in the US.

The US Food and Drug Administration approved the Phase 3 protocol for the trial in January, the company added.

Shares of Annovis were down 1.4% in recent trading.

Price: 3.10, Change: -0.04, Percent Change: -1.43

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2509236983?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-06 00:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2509236983","market":"us","top_or_hot":-1,"title":"Annovis Bio Enrolls First Patients in Phase 3 Trial of Buntanetap for Early Alzheimer's Disease","media":"MT Newswires Live","content":"<html><body><p> Annovis Bio (ANVS) said Wednesday it enrolled the first two participants in its phase 3 trial of buntanetap for early Alzheimer's disease.</p><p>The trial will evaluate the safety and efficacy of a daily dose of buntanetap, with treatment lasting for 18 months.</p><p>The study includes a 6-month assessment of symptomatic effects followed by a 12-month evaluation of potential disease-modifying effects. Annovis said it plans to enroll more than 750 patients across about 100 sites in the US.</p><p>The US Food and Drug Administration approved the Phase 3 protocol for the trial in January, the company added.</p><p>Shares of Annovis were down 1.4% in recent trading.</p><p>Price: 3.10, Change: -0.04, Percent Change: -1.43</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Annovis Bio Enrolls First Patients in Phase 3 Trial of Buntanetap for Early Alzheimer's Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnnovis Bio Enrolls First Patients in Phase 3 Trial of Buntanetap for Early Alzheimer's Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-06 00:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Annovis Bio (ANVS) said Wednesday it enrolled the first two participants in its phase 3 trial of buntanetap for early Alzheimer's disease.</p><p>The trial will evaluate the safety and efficacy of a daily dose of buntanetap, with treatment lasting for 18 months.</p><p>The study includes a 6-month assessment of symptomatic effects followed by a 12-month evaluation of potential disease-modifying effects. Annovis said it plans to enroll more than 750 patients across about 100 sites in the US.</p><p>The US Food and Drug Administration approved the Phase 3 protocol for the trial in January, the company added.</p><p>Shares of Annovis were down 1.4% in recent trading.</p><p>Price: 3.10, Change: -0.04, Percent Change: -1.43</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2509236983","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2509236983","pubTimestamp":1738771584,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Annovis Bio  said Wednesday it enrolled the first two participants in its phase 3 trial of buntanetap for early Alzheimer's disease.The trial will evaluate the safety and efficacy of a daily dose of buntanetap, with treatment lasting for 18 months.The study includes a 6-month assessment of symptomatic effects followed by a 12-month evaluation of potential disease-modifying effects. Annovis said it plans to enroll more than 750 patients across about 100 sites in the US.The US Food and Drug Administration approved the Phase 3 protocol for the trial in January, the company added.Shares of Annovis were down 1.4% in recent trading.Price: 3.10, Change: -0.04, Percent Change: -1.43","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ANVS":"Annovis Bio, Inc."},"translate_title":"Annovis Bio在Buntanetap治疗早期阿尔茨海默病的3期试验中招募了第一批患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANVS":1},"content_text":"Annovis Bio (ANVS) said Wednesday it enrolled the first two participants in its phase 3 trial of buntanetap for early Alzheimer's disease.The trial will evaluate the safety and efficacy of a daily dose of buntanetap, with treatment lasting for 18 months.The study includes a 6-month assessment of symptomatic effects followed by a 12-month evaluation of potential disease-modifying effects. Annovis said it plans to enroll more than 750 patients across about 100 sites in the US.The US Food and Drug Administration approved the Phase 3 protocol for the trial in January, the company added.Shares of Annovis were down 1.4% in recent trading.Price: 3.10, Change: -0.04, Percent Change: -1.43","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2509236983","isCrawlerRequest":true}